Is Gabapentin Habit Forming? Dependence Explained

Gabapentin can produce physical dependence, and a subset of people do misuse it for its psychoactive effects, but the drug does not appear to carry the same addictive pull as classic drugs of abuse when used on its own. The risk is heavily concentrated among people with a history of opioid or other substance use disorders. For the general population taking gabapentin as prescribed, the chance of developing problematic use is low, though withdrawal symptoms can still occur if the drug is stopped abruptly after long-term use.

How Gabapentin Works in the Brain

Despite having “GABA” in its name, gabapentin does not actually work on GABA receptors the way drugs like benzodiazepines or alcohol do. Instead, it binds to a specific part of voltage-gated calcium channels called the alpha-2-delta subunit.¹ By latching onto these subunits, gabapentin reduces the release of excitatory signaling molecules in the nervous system. This is what makes it useful for nerve pain, seizures, and certain anxiety conditions. The effect is calming, sometimes described as a mild sense of relaxation or even mild euphoria at higher doses, which is the quality that attracts recreational misuse.

What gabapentin does not do, under normal circumstances, is flood the brain’s reward center with dopamine the way opioids or stimulants do. Multiple investigations have found no meaningful dopamine surge in the brain’s reward pathway when gabapentin is given to healthy animals or to humans without chronic pain.² A systematic review found only four documented cases of someone with no prior substance use history developing genuine dependence on gabapentin, with weak evidence of the compulsive reward-seeking behavior that defines addictive drugs.² That said, animal research has shown that at high doses, gabapentin can produce place-preference behavior (a sign a drug is rewarding), and this effect appears to involve the dopamine system.³ So the picture is more complicated than “gabapentin has zero abuse potential.”

Who Is Most Likely to Misuse Gabapentin

The risk of gabapentin misuse is not evenly distributed. In the general population, misuse sits around 1%. But among people with opioid use disorders, estimates range from about 15% to 26%, depending on the study and how misuse is defined.⁴ One study found that 26% of patients with opioid addiction endorsed illegally obtaining, overusing, or faking symptoms to get gabapentin, compared to just 4% of patients without an opioid use disorder.⁵ A broader systematic review confirmed that opioid use disorder is the single greatest risk factor for gabapentinoid misuse.⁶

Why opioid users in particular? Part of the reason is pharmacological: gabapentin can amplify the euphoria of opioids and ease opioid withdrawal symptoms, making it attractive as a booster or bridge drug. Part of it is behavioral: people with one substance use disorder are statistically more likely to develop another. In a review of 18 published case reports and series on gabapentin addiction, every patient who became addicted had a prior history of alcohol, cocaine, or opioid abuse. Most were taking more than 3,000 mg per day, well above typical prescribed doses.⁷

Other risk factors that increase the odds of gabapentinoid misuse include younger age, depression, having multiple prescribers, and receiving concurrent methadone treatment.⁸ A large UK study using primary care records found that a history of any mental health condition, previous overdose, or prior substance misuse all significantly increased the risk of adverse outcomes like drug misuse and overdose in patients prescribed gabapentinoids.⁹

Physical Dependence and Withdrawal

Even people taking gabapentin exactly as prescribed can develop physical dependence over time. Physical dependence just means your body has adapted to the drug’s presence, so removing it abruptly causes withdrawal symptoms. This is different from addiction, which involves compulsive use despite harm. You can be physically dependent on gabapentin without being addicted to it, the same way someone on blood pressure medication might experience rebound hypertension if they stop suddenly.

Gabapentin withdrawal is real and can be unpleasant. Reported symptoms include anxiety, insomnia, nausea, sweating, pain, and in more severe cases, confusion, rapid heart rate, and elevated blood pressure. In one documented case, a patient who had her gabapentin tapered still developed moderate symptoms that gradually worsened over about ten days until she acutely developed severe mental status changes, chest pain, and hypertension. Restarting gabapentin brought her back to baseline within a day or two.¹⁰ Seizures have also been reported during withdrawal, even in people who were not taking gabapentin for epilepsy.

There is no universally agreed-upon tapering protocol. General guidance is to reduce the dose gradually over at least a week, though many clinicians use longer timelines for patients who have been on gabapentin for months or years. In one extreme case, a patient with alcohol use disorder required an 18-month taper. She reduced her daily dose by about 100 mg per month until reaching 300 mg, then slowed to 20-to-30-mg decrements per month, and eventually tapered the final stretch at just 5 mg every one to two weeks.¹¹ That case is unusual, but it illustrates that some individuals develop a sensitivity to even small dose reductions. The practical takeaway: never stop gabapentin cold turkey, and if a slow taper is still causing symptoms, ask your prescriber about making smaller decreases.

The Danger of Combining Gabapentin With Opioids

Where gabapentin goes from “low-risk when used alone” to genuinely dangerous is when it is combined with opioids. This combination can suppress breathing beyond what either drug would do on its own. A large population-based study in Ontario found that people prescribed both gabapentin and opioids had roughly 50% higher odds of opioid-related death compared to people on opioids alone, after adjusting for other factors. The risk climbed with the gabapentin dose: moderate and high doses were each associated with close to a 60% increase in the odds of dying from an opioid-related cause.¹²

A separate study of surgical patients in the United States found that adding gabapentinoids to opioid therapy nearly doubled the hazard of overdose and raised the risk of respiratory complications by about 70%.¹³ And in a study of Medicare beneficiaries with noncancer pain, people using gabapentin alongside high-dose opioids had roughly double the all-cause mortality rate compared to people using duloxetine alongside high-dose opioids.² These findings are consistent across different study designs and populations, which makes them hard to dismiss. If you are taking both gabapentin and an opioid, the combination deserves a serious conversation with your doctor about whether the benefit justifies the added risk.

Gabapentin and Kidney Function

Gabapentin is cleared almost entirely by the kidneys. It is not broken down by the liver and passes through the body largely unchanged. When kidney function declines, the drug accumulates in the bloodstream and can reach toxic levels at doses that would be perfectly safe for someone with healthy kidneys.¹⁴

A study examining gabapentin toxicity in patients with varying degrees of kidney function found that toxicity occurred exclusively in those with reduced kidney clearance, and the severity was markedly worse in the group with the most impaired kidneys. Elderly patients with multiple health conditions were overrepresented among those who developed toxic symptoms.¹⁵ Toxicity can look like extreme drowsiness, confusion, slurred speech, and unsteadiness. These symptoms sometimes get mistaken for a stroke or new neurological problem rather than recognized as a medication side effect. If you or an older family member takes gabapentin and has kidney problems, the dose should be adjusted downward, and blood levels may need monitoring.

How Some States Have Responded

Gabapentin is not a federally controlled substance in the United States, meaning the DEA does not classify it alongside opioids, benzodiazepines, or other scheduled drugs. However, growing awareness of misuse has led several states to act on their own. Some states have classified gabapentin as a Schedule V controlled substance (the least restrictive category, similar to cough syrup with codeine), while others have added it to their prescription drug monitoring programs without full scheduling.

These policy moves appear to have an effect. A study examining Medicare prescribing data found that states classifying gabapentin as Schedule V saw a reduction of about eight days of total gabapentin prescribed per enrollee, while states that simply added it to their monitoring databases saw a smaller but still measurable drop of about one day per enrollee.¹⁶ The debate over scheduling is a real tension: tighter controls reduce misuse but can also create barriers for the many patients who take gabapentin safely and benefit from it for chronic pain, neuropathy, or seizure control.

How Gabapentin Compares to Pregabalin

Pregabalin (Lyrica) is gabapentin’s close cousin. Both bind to the same alpha-2-delta calcium channel subunit, but pregabalin is more potent, gets absorbed faster, and has higher bioavailability, meaning a larger fraction of each dose reaches the bloodstream.¹⁷ These pharmacological differences matter for abuse potential. Pregabalin tends to produce a quicker, more pronounced effect, which makes it more reinforcing for people seeking a high. One French cohort study found that pregabalin use carried about a 50% higher hazard of misuse compared to gabapentin, after controlling for other factors.⁸ Pregabalin is already a Schedule V controlled substance at the federal level in the United States, a distinction gabapentin has not received nationally. If you have been prescribed one and are curious about switching to the other, the abuse-potential difference is one factor your prescriber will weigh alongside pain control and side effects.

The Dopamine Question

Much of the debate about gabapentin’s habit-forming potential comes down to dopamine. Classic drugs of abuse hijack the brain’s reward pathway by causing surges of dopamine in a region called the nucleus accumbens. Research consistently shows that gabapentin does not produce this effect in healthy brains.² But in brains already altered by chronic pain or substance use disorders, the picture shifts. Animal studies using chronic pain models have detected dopamine elevation in the reward pathway when gabapentin is administered, suggesting the drug’s rewarding properties may emerge only in neurologically sensitized states.

Recent research has also found that gabapentin misuse is linked to changes in the balance between two types of dopamine receptors. In a study comparing gabapentin misuse to withdrawal, people misusing gabapentin showed significant upregulation of one dopamine receptor type and downregulation of another, a pattern associated with drug-seeking behavior.¹⁸ This helps explain the paradox: gabapentin appears to have essentially no addictive pull in most people, yet it behaves differently in brains that are already wired for substance-seeking. The implication for clinicians is straightforward, and multiple reviews have arrived at the same conclusion: gabapentin is generally safe in patients without a substance use history, but prescribing it to someone with active or recent opioid addiction demands careful monitoring.

Gabapentin Exposure in Pregnancy and Neonatal Withdrawal

Gabapentin crosses the placenta. Case reports have documented neonatal withdrawal syndrome in infants born to mothers who took gabapentin throughout pregnancy.¹⁹ Symptoms in affected newborns resemble those seen in neonatal opioid withdrawal: irritability, jitteriness, feeding difficulties, and in some cases more serious signs requiring medical intervention.

When gabapentin is combined with opioid exposure during pregnancy, the risk of neonatal withdrawal climbs substantially. A large cohort study found that among neonates exposed in utero to prescription opioids alone, the risk of drug withdrawal was about 1%. Adding gabapentin exposure pushed that number to about 11%, and the adjusted relative risk of withdrawal with gabapentin co-exposure was roughly 60% higher than with opioids alone.²⁰ Among the psychotropic medications studied alongside opioids, gabapentin carried one of the highest relative risks. Pregnant individuals taking gabapentin, especially alongside opioids, should discuss the risk with their obstetrician, though abruptly stopping either drug during pregnancy is also dangerous and should never be done without medical guidance.